| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BCRX Stock Overview
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.
BioCryst Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.76 |
| 52 Week High | US$19.99 |
| 52 Week Low | US$7.61 |
| Beta | 2.51 |
| 1 Month Change | 22.27% |
| 3 Month Change | -32.71% |
| 1 Year Change | -37.19% |
| 3 Year Change | 183.91% |
| 5 Year Change | 93.53% |
| Change since IPO | 65.54% |
Recent News & Updates
BioCryst: A Prudent Diversification
BioCryst Pharmaceuticals shares have been clobbered due to both the bear market and the uncertainty relating to its lead developing drug (BCX9930). I believe that the FDA would remove the partial clinical hold on BCX9930 by either year-end or next year. The lead drug (Orladeyo) is enjoying robust sales increase due to various launched catalysts.
Shareholder Returns
| BCRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.9% | 10.3% | 6.6% |
| 1Y | -37.2% | -24.4% | -18.5% |
Return vs Industry: BCRX underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: BCRX underperformed the US Market which returned -20.5% over the past year.
Price Volatility
| BCRX volatility | |
|---|---|
| BCRX Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 13.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: BCRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 358 | Jon Stonehouse | https://www.biocryst.com |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
BioCryst Pharmaceuticals Fundamentals Summary
| BCRX fundamental statistics | |
|---|---|
| Market Cap | US$1.89b |
| Earnings (TTM) | -US$193.97m |
| Revenue (TTM) | US$188.03m |
10.6x
P/S Ratio-10.3x
P/E RatioIs BCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCRX income statement (TTM) | |
|---|---|
| Revenue | US$188.03m |
| Cost of Revenue | US$233.35m |
| Gross Profit | -US$45.31m |
| Other Expenses | US$148.66m |
| Earnings | -US$193.97m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | -24.10% |
| Net Profit Margin | -103.16% |
| Debt/Equity Ratio | -368.1% |
How did BCRX perform over the long term?
See historical performance and comparisonValuation
Is BCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BCRX?
Other financial metrics that can be useful for relative valuation.
| What is BCRX's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$1.89b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 10.9x |
| Enterprise Value/EBITDA | -11.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BCRX's PS Ratio compare to its peers?
| BCRX PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 92.1x |
Price-To-Sales vs Peers: BCRX is good value based on its Price-To-Sales Ratio (10.6x) compared to the peer average (92.1x).
Price to Earnings Ratio vs Industry
How does BCRX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: BCRX is good value based on its Price-To-Sales Ratio (10.6x) compared to the US Biotechs industry average (13.8x)
Price to Sales Ratio vs Fair Ratio
What is BCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.6x |
| Fair PS Ratio | 3.9x |
Price-To-Sales vs Fair Ratio: BCRX is expensive based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).
Share Price vs Fair Value
What is the Fair Price of BCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BCRX ($10.76) is trading below our estimate of fair value ($46.48)
Significantly Below Fair Value: BCRX is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BCRX's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
68.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCRX's revenue (23.2% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: BCRX's revenue (23.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has BioCryst Pharmaceuticals performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-27.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BCRX is currently unprofitable.
Growing Profit Margin: BCRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.
Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: BCRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is BioCryst Pharmaceuticals's financial position?
Financial Health Score
1/6Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BCRX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BCRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BCRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BCRX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Jon Stonehouse (60 yo)
15.42yrs
Tenure
US$7,061,225
Compensation
Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining on January 8, 2007 and also has been its President...
CEO Compensation Analysis
Compensation vs Market: Jon's total compensation ($USD7.06M) is about average for companies of similar size in the US market ($USD5.50M).
Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: BCRX's management team is considered experienced (2.4 years average tenure).
Board Members
Experienced Board: BCRX's board of directors are considered experienced (3.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.
Top Shareholders
Company Information
BioCryst Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: BioCryst Pharmaceuticals, Inc.
- Ticker: BCRX
- Exchange: NasdaqGS
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.887b
- Shares outstanding: 185.58m
- Website: https://www.biocryst.com
Number of Employees
Location
- BioCryst Pharmaceuticals, Inc.
- 4505 Emperor Boulevard
- Suite 200
- Durham
- North Carolina
- 27703
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/24 00:00 |
| End of Day Share Price | 2022/06/24 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.